{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-23-000099","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.990957+00:00","generated_at":"2026-06-10T00:21:04.018527+00:00","sec_items":["2.02","2.05","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Pfizer cuts FY2023 revenue guide by $9B, records $5.5B COVID write-off, amends Paxlovid deal","bullets":["Revises 2023 revenue to $58-61B (from $67-70B); Paxlovid revenues cut ~$7B including $4.2B reversal.","Records $5.5B non-cash Q3 charge for COVID inventory write-offs ($4.6B Paxlovid, $0.9B Comirnaty).","Amended U.S. Paxlovid deal: return ~7.9M EUA courses at year-end; commercial transition Jan 1, 2024.","Launches cost realignment program targeting $3.5B savings ($1B in 2023, $2.5B in 2024); ~$3B one-time costs.","Adjusted diluted EPS guidance cut to $1.45-$1.65 from $3.25-$3.45; non-COVID product growth reaffirmed at 6-8%."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-23-000099","json":"https://secwatch.observer/filing/0000078003-23-000099.json","markdown":"https://secwatch.observer/filing/0000078003-23-000099.md","text":"https://secwatch.observer/filing/0000078003-23-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000099/0000078003-23-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000099/pfe-20231013.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T00:21:04.018527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64480aa26a35cbb66ebbad258a5e07ec43c43596","claim":"PFIZER INC reported Full-Year 2023 results: EPS $1.45 to $1.65. Guidance lowered.","evidence_excerpt":"Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000099/0000078003-23-000099-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full-Year 2023"},{"label":"EPS","value":"$1.45 to $1.65"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"d87fcb66033ca2c08fd687b5b0ea53d58400e797","claim":"PFIZER INC announced a restructuring with charges of approximately $3.0 billion affecting enterprise-wide.","evidence_excerpt":"$2.5 billion is expected to be realized in 2024. The one-time costs to achieve the savings associated with the Cost Realignment Program are expected to be approximately $3.0 billion, of which the majority is expected to be cash. These costs will primarily include severance and implementation costs. The estimate of costs that Pfizer expects to incur, and the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000099/0000078003-23-000099-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.0 billion"},{"label":"Affected area","value":"enterprise-wide"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}